WHAT IS CLAIMED IS:

1. A composition for treating a hyperproliferative disease, comprising:
a first agent selected from the group consisting of:
(i) an agent that possesses anti-inflammatory activity;
(ii) acetaminophen;
(iii) phenacetin;
(iv) tramadol; and
(v) pharmaceutically acceptable salts, prodrugs and solvates of (i)-(iv); and
a second agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator, and their pharmaceutically acceptable salts, prodrugs, and solvates.

2. The composition of claim 1, wherein the hyperproliferative disease is a benign tumor.

3. The composition of claim 1 wherein the hyperproliferative disease is cancerous.

4. The composition of claim 1, wherein the composition decreases proliferation of hyperproliferative cells.

5. The composition of claim 1, further comprising a third agent that possesses or maintains serotonin activity.

6. The composition of claim 5 wherein the hyperproliferative disease is a tumor and said composition kills a portion of the tumor.

7. The composition of claim 5 wherein the hyperproliferative disease is a tumor and said composition inhibits metastasis of the tumor.

8. The composition of claim 1 wherein the first agent is selected from the group consisting of

(i) an agent that possesses anti-inflammatory activity,

(ii) acetaminophen,

(iii) phenacetin, and

(iv) tramadol.

9. The composition of claim 8, further comprising a third agent that possesses or maintains serotonin activity.

10. The composition of claim 8 or 9, wherein the second agent is selected from the group consisting of metformin, phenformin and buformin and their pharmaceutically acceptable salts, prodrugs and solvates.

11. The composition of claim 8 or 9, wherein the first agent is a non-steroidal anti-inflammatory compound.

12. The composition of claim 8 or 9, wherein the first agent is selected from the group consisting of:

(i) aspirin, diclofenac, ibuprofen, indomethacin, acetaminophen, nimesulide, and their pharmaceutically acceptable salts, prodrugs and solvates; and

(ii) a COX-2 inhibitor.

13. The composition of claim 8 or 9, wherein the first agent is aspirin, L-arginine-acetylsalicylic acid, aspirin-DL-lysine or celecoxib.

14. The composition of claim 9, wherein the third agent is serotonin or a serotonin re-uptake inhibitor.

15. The composition of claim 14, wherein the third agent is serotonin sulfate, serotonin creatinine sulfate complex, or serotonin hydrochloride.

16. The composition of claim 8 or 9, wherein the composition contains 1-5000 mg of the first agent, 5-5000 mg of the second agent, and where a third agent is present, 0.1-1000 mg of the third agent; or in quantities of the same ratio.

17. The composition of claim 8 or 9, wherein the composition contains 1-3000 of the first agent, 5-1500 mg of the second agent, and where a third agent is present, 0.1-500 mg of the third agent; or in quantities of the same ratio.

18. The composition of claim 8 or 9, wherein the composition contains 1-1000 mg of the first agent, 5-1000 mg of the second agent, and where a third agent is present, 0.1-100 mg of the third agent; or in quantities of the same ratio.

19. The composition of claim 9, wherein the composition contains:
(i) metformin hydrochloride;
(ii) aspirin, L-arginine acetylsalicylic acid, or aspirin-DL-lysine, and
(iii) serotonin creatinine sulfate complex or serotonin hydrochloride.

20. The composition of claims 8 or 9, wherein the composition further comprises a pharmaceutically acceptable carrier.

21. The composition of claim 9, wherein the composition consists essentially of the first, second, and third agents.

22. The composition of claim 8 or 9, wherein the second agent is an AMPK activator.

23. The composition of claim 22, wherein the AMPK activator is selected from the group consisting of metformin, phenformin, buformin, AICAR, thienopyridones, resveratrol, nootkatone, thiazole, adiponectin, thiazolidinediones, rosiglitazone, pioglitazone and dithiolethiones.

24. The composition of claim 8 or 9, wherein the second agent is an oxidative phosphorylation inhibitor or ionophore.

25. The composition of claim 12 wherein the first agent is aspirin or a COX-2 inhibitor.

26. The composition of claim 8 or 9 wherein the composition further comprises a carrier substance that is useful in carrying the composition to the intended site of action.

27. The composition of claim 26 wherein the second agent is selected from the group consisting of metformin, phenformin, and their pharmaceutically acceptable salts, prodrugs and solvates and the second agent is linked to an antibody.

28. The composition of claim 8 wherein the first agent is selected from the group consisting of aspirin, celecoxib, and their pharmaceutically acceptable salts, prodrugs and solvates, wherein the second agent is selected from the group consisting of metformin, phenformin, and their pharmaceutically acceptable salts, prodrugs and solvates, and where at least one of the first agent and the second agent is covalently bonded to an immunoglobulin that is specific for a marker found on hyperproliferative cells of a patient targeted for treatment.

29. The composition of claim 28 wherein the immunoglobulin is IgG.

30. The composition of claim 9 wherein the third agent is selected from the group consisting of serotonin and its pharmaceutically acceptable salts, prodrugs and solvates.

31. The composition of claim 8 wherein the first and second agents are attached to their own individual carrier substances that facilitate the transport of the active agents to the intended site of action.

32. The composition of claim 9 wherein the first, second and third agents are attached to their own individual carrier substances that facilitate the transport of the active agents to the intended site of action.

33. A composition for treating a hyperproliferative disease comprising:
(a) an active agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an AMPK activator; and
(b) a carrier substance to which the active agent is attached and that facilitates the transport of the active agent to the intended site of action.

34. The composition of claim 33 wherein the active agent is an AMPK activator.

35. The composition of claim 33 wherein the active agent is an oxidative phosphorylation inhibitor or ionophore.

36. Use of the composition of any of claims 1 to 35 for preparation of a medicament for treatment of a hyperproliferative disease.

37. The use of claim 36 wherein the medicament manufactured from the composition is administered parenterally or orally.

38. The use of claim 36 wherein the hyperproliferative disease is a solid tumor and the composition is injected directly into the tumor.

39. The use of claim 36 wherein the medicament manufactured from the composition decreases proliferation.

40. The use of claim 36 wherein the medicament manufactured from the composition kills cells that cause the hyperproliferative disease.

41. The use of claim 36 wherein the medicament manufactured from the composition inhibits metastasis of hyperproliferative cells.

42. The use of claim 36 wherein the hyperproliferative disease is a benign tumor.

43. The use of claim 36 wherein the hyperproliferative disease is a malignant tumor.

44. The use of claim 36 wherein the hyperproliferative disease is a solid tumor.

45. The use of claim 36 wherein the first agent is selected from the group consisting of aspirin and celecoxib and their pharmaceutically acceptable salts, prodrugs and solvates, wherein the second agent is selected from the group consisting of metformin and phenformin and their pharmaceutically acceptable salts, prodrugs and solvates, and wherein the composition further comprises a carrier substance that is useful in carrying the composition to the intended site of action.

46. The use of claim 45 wherein the metformin or phenformin or their pharmaceutically acceptable salts, prodrugs and solvates is linked to an antibody.

47. The use of claim 45 wherein at least one of: (i) metformin or phenformin or their pharmaceutically acceptable salts, prodrugs and solvates and (ii) aspirin or celecoxib or their pharmaceutically acceptable salts, prodrugs and solvates is covalently bonded to an immunoglobulin that is specific for a marker found on the hyperproliferative cells of the patient that are targeted for treatment.

48. The use of claim 47 wherein the immunoglobulin is IgG.

49. The use of any of claims 44 to 48 wherein the medicament manufactured from the composition is administered intravenously.

50. The use of any of claims 44 to 48 wherein the medicament manufactured from the

composition is administered orally.

51. The use of any of claims 44 to 48 wherein:

(i) the amount of the medicament manufactured from the composition needed to provide a therapeutic effect is less than the amount of the composition needed to provide a therapeutic effect when not administered with a carrier substance;

(ii) the patient experiences less toxicity to healthy cells relative to the toxicity experienced when the medicament manufactured from the composition is administered without a carrier substance; or

(iii) the patient experiences fewer adverse effects relative to the adverse effects experienced when the medicament manufactured from the composition is administered without a carrier substance.

52. The use of claim 36 wherein the composition comprises a first agent selected from the group consisting of:

(i) an agent that possesses anti-inflammatory activity,

(ii) acetaminophen,

(iii) phenacetin, and

(iv) tramadol;

a second agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an AMPK activator; and a third agent that possesses or maintains serotonin activity.

53. The use of claim 52 wherein the second agent is an AMPK activator.

54. The use of claim 52 wherein the second agent is an oxidative phosphorylation inhibitor or ionophore.

55. The use of claim 36 wherein the composition comprises a first agent selected from the group consisting of:

(a) a first agent selected from the group consisting of:

(i) an agent that possesses anti-inflammatory activity,
(ii) acetaminophen,
(iii) phenacetin, and
(iv) tramadol;
(b) a second agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an AMPK activator; and
(c) a third agent that possesses or maintains serotonin activity; and
wherein the first, second and third agents are attached to their own individual carrier substances that facilitate the transport of the active agents to the intended site of action.

56. The use of claim 36 wherein the composition comprises a first agent selected from the group consisting of:
(i) an agent that possesses anti-inflammatory activity,
(ii) acetaminophen,
(iii) phenacetin, and
(iv) tramadol; and
a second agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an AMPK activator; and
a third agent that possesses or maintains serotonin activity; and
wherein the first and second agents are attached to their own individual carrier substances that facilitate the transport of the active agents to the intended site of action.

57. The use of claim 55 or 56 wherein the second agent is an AMPK activator.

58. The use of claim 55 or 56 wherein the second agent is an oxidative phosphorylation inhibitor or ionophore.

59. The use of claim 55 or 56 wherein the carrier substance is an antibody.

60. The use of claim 59 wherein the antibody is specific for a marker on the cells of the hyperproliferative disease.

61. The use of claim 36 wherein the composition comprises:

(a) an active agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an AMPK activator; and

(b) a carrier substance to which the active agent is attached and that facilitates the transport of the active agent to the intended site of action.

62. The use of claim 61 wherein the active agent is selected from the group consisting of metformin and phenformin and their pharmaceutically acceptable salts, prodrugs and solvates and the carrier substance is an antibody specific to a marker on the cells of the hyperproliferative disease.

63. The use of claim 61 wherein the active agent is an AMPK activator.

64. The use of claim 61 wherein the active agent is an oxidative phosphorylation inhibitor or ionophore.

65. The use of claim 61 wherein the hyperproliferative disease is colon cancer.

66. Use of the composition of any of claims 1 to 35 for preparation of a medicament for inhibiting metastasis.

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising:

a first agent selected from the group consisting of: (i) an agent that possesses anti-inflammatory activity that is selected from the group consisting of hydrocortisone, beclomethasone, betamethasone, dexamethasone, prednisone, methylprednisolone, triamcinolone, fluocinolone, fludrocortisone, aceclofenac, acemetacin, acetylsalicylic acid, alclofenac, alminoprofen, ampiroxicam, amtolmetin guacil, apazone, atliprofen methyl ester, benoxaprofen, bermoprofen, bromfenac, bucloxic acid, butibufen, carprofen, celecoxib, choline magnesium trisalicylate, cimicoxib, cinnoxicam, clidanac, COX-2 inhibitors, darbufelone, deracoxib, dexketoprofen, diclofenac, diflunisal, eltenac, esflurbiprofen, etoricoxib, etodolac, felbinac ethyl, fenbufen, fenclofenac, fenclozic acid, fenclozine, fenoprofen, fentiazac, feprazone, filenadol, flobufen, florifenine, flosulide, flubichin methanesulfonate, flufenamic acid, fluprofen, flurbiprofen, furofenac, ibufenac, ibuproxam-beta-cyclodextrin, imrecoxib, indoprofen, isoxepac, isoxicam, ketoprofen, licofelone, lobuprofen, lumiracoxib, mabuprofen, meclofenamic acid, mefenamic acid, meloxicam, metoxibutropate, miroprofen, mofebutazone, mofezolac, nabumetone, naproxen, niflumic acid, nimesulide, nitrofenac, nitroflurbiprofen, nitronaproxen, orpanoxin, oxaprozin, oxindanac, oxpinac, oxyphenbutazone, pamicogrel, parcetasal, parecoxib, pelubiprofen, pemedolac, phenylbutazone, pirazolac, piroxicam, piroxicam beta-cyclodextrin, pirprofen, pranoprofen, rofecoxib, salicylsalicylic acid, salsalate, satigrel, sodium salicylate, sudoxicam, sulfasalazine, sulindac, suprofen, talmetacin, talniflumate, tazofelone, tebufelone, tenidap, tepoxalin, tiaprofenic acid, tilmacoxib, tilnoprofen arbamel, tinoridine, tiopinac, tioxaprofen, tolfenamic acid, tolmetin, triflusal, tropesin, ursolic acid, valdecoxib, ximoprofen, zaltoprofen, zidometacin, zomepirac, L-arginine acetylsalicylic acid, bismuth salicylate, magnesium salicylate, diethylamine salicylate, salicylic acid, imidazole salicylate, sodium aminosalicylate, isoniazid aminosalicylate, physostigmine salicylate, pregnenolone salicylate, sodium salicylate, and methylsalicylate; (ii) acetaminophen; (iii) phenacetin ;and (iv) tramadol;

a second agent that is an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator; and

a third agent that possesses or maintains serotonin activity.

2. The composition of claim 1 wherein the third agent that possesses or maintains serotonin activity is serotonin, serotonin sulfate, serotonin creatinine sulfate complex, or serotonin hydrochloride or a serotonin reuptake inhibitor.

3. The composition of any of claims 1 or 2, wherein the second agent is selected from the group consisting of metformin, phenformin and buformin.

4. The composition of any of claims 1 to 3, wherein the first agent is a non-steroidal anti-inflammatory compound selected from the group consisting of aceclofenac, acemetacin, acetylsalicylic acid, alclofenac, alminoprofen, ampiroxicam, amtolmetin guacil, apazone, atliprofen methyl ester, benoxaprofen, bermoprofen, bromfenac, bucloxic acid, butibufen, carprofen, celecoxib, choline magnesium trisalicylate, cimicoxib, cinnoxicam, clidanac, COX-2 inhibitors, darbufelone, deracoxib, dexketoprofen, diclofenac, diflunisal, eltenac, esflurbiprofen, etoricoxib, etodolac, felbinac ethyl, fenbufen, fenclofenac, fenclozic acid, fenclozine, fenoprofen, fentiazac, feprazone, filenadol, flobufen, florifenine, flosulide, flubichin methanesulfonate, flufenamic acid, fluprofen, flurbiprofen, furofenac, ibufenac, ibuproxam-beta-cyclodextrin, imrecoxib, indoprofen, isoxepac, isoxicam, ketoprofen, licofelone, lobuprofen, lumiracoxib, mabuprofen, meclofenamic acid, mefenamic acid, meloxicam, metoxibutropate, miroprofen, mofebutazone, mofezolac, nabumetone, naproxen, niflumic acid, nimesulide, nitrofenac, nitroflurbiprofen, nitronaproxen, orpanoxin, oxaprozin, oxindanac, oxpinac, oxyphenbutazone, pamicogrel, parcetasal, parecoxib, pelubiprofen, pemedolac, phenylbutazone, pirazolac, piroxicam, piroxicam beta-cyclodextrin, pirprofen, pranoprofen, rofecoxib, salicylsalicylic acid, salsalate, satigrel, sodium salicylate, sudoxicam, sulfasalazine, sulindac, suprofen, talmetacin, talniflumate, tazofelone, tebufelone, tenidap, tepoxalin, tiaprofenic acid, tilmacoxib, tilnoprofen arbamel, tinoridine, tiopinac, tioxaprofen, tolfenamic acid, tolmetin, triflusal, tropesin, ursolic acid, valdecoxib, ximoprofen, zaltoprofen, zidometacin, zomepirac, acetaminophen, phenacetin, tramadol, L-arginine acetylsalicylic acid, bismuth salicylate, magnesium salicylate, diethylamine salicylate, salicylic acid, imidazole salicylate, sodium aminosalicylate, isoniazid aminosalicylate, physostigmine salicylate, pregnenolone salicylate, sodium salicylate, and methylsalicylate.

5. The composition of any of claims 1 to 3, wherein the first agent is selected from the group consisting of: (i) aspirin, diclofenac, ibuprofen, indomethacin, acetaminophen, nimesulide, celecoxib, piroxicam, and tramadol; and (ii) a COX-2 inhibitor.

6. The composition of any of claims 1 to 3, wherein the first agent is aspirin, L-arginine-acetylsalicylic acid, aspirin-DL-lysine or celecoxib.

7. The composition of claim 1, wherein the third agent is serotonin sulfate, serotonin creatinine sulfate complex, or serotonin hydrochloride.

8. The composition of any of claims 1 through 7, wherein the composition contains 1-5000 mg of the first agent, 5-5000 mg of the second agent, and where a third agent is present, 0.1-1000 mg of the third agent.

9. The composition of claim 9, wherein the composition contains 1-3000 mg of the first agent, 5-1500 mg of the second agent, and where a third agent is present, 0.1-500 mg of the third agent.

10. The composition of claim 9,wherein the composition contains 1-1000 mg of the first agent, 5-1000 mg of the second agent, and where a third agent is present, 0.1-100 mg of the third agent.

11. The composition of claim 1, wherein the composition contains: (i) metformin hydrochloride; (ii) aspirin, celecoxib, L-arginine acetylsalicylic acid, or aspirin-DL-lysine, and (iii) serotonin creatinine sulfate complex or serotonin hydrochloride.

12. The composition of any of claims 1 through 10, wherein the composition further comprises a pharmaceutically acceptable carrier.

13. The composition of claim 1, wherein the composition consists essentially of the first, second, and third agents.

14. The composition of claim 1, wherein the second agent is an AMPK activator.

15. The composition of claim 14, wherein the AMPK activator is selected from the group consisting of metformin, phenformin, buformin, AICAR, thienopyridones, resveratrol, nootkatone, thiazole, adiponectin, thiazolidinediones, rosiglitazone, pioglitazone and dithiolethiones.

16. The composition of claim 1, wherein the first agent is aspirin, celecoxib or a COX-2 inhibitor.

17. The composition of claim 1 wherein the composition further comprises a carrier substance that is useful in carrying the composition to the intended site of action.

18. The composition of claim 17 wherein the second agent is selected from the group consisting of metformin and phenformin and the second agent is linked to an antibody.

19. The composition of claim 17 wherein the first agent is selected from the group consisting of aspirin and celecoxib, wherein the second agent is selected from the group consisting of metformin and phenformin, and where at least one of the first agent and the second agent is covalently bonded to an immunoglobulin that is specific for a marker found

on hyperproliferative cells of a patient targeted for treatment.

20. The composition of claim 19 wherein the immunoglobulin is IgG.

21. The composition of claim 1 wherein the third agent is serotonin.

22. The composition of claim 1 wherein the first and second agents are attached to their own individual carrier substances that facilitate the transport of the active agents to the intended site of action.

23. The composition of claim 1 wherein the first, second and third agents are attached to their own individual carrier substances that facilitate the transport of the active agents to the intended site of action.

24. Use of the composition of any of claims 1 to 23 for preparation of a medicament for treatment of a hyperproliferative disease.

25. The use of claim 24 wherein the medicament manufactured from the composition is administered parenterally or orally.

26. The use of claim 24 wherein the hyperproliferative disease is a solid tumor and the composition is injected directly into the tumor.

27. The use of claim 24 wherein the medicament manufactured from the composition decreases proliferation.

28. The use of claim 24 wherein the medicament manufactured from the composition kills cells that cause the hyperproliferative disease.

29. The use of claim 24 wherein the medicament manufactured from the composition inhibits metastasis of hyperproliferative cells.

30. The use of claim 24 wherein the hyperproliferative disease is a benign tumor.

31. The use of claim 24 wherein the hyperproliferative disease is a malignant tumor.

32. The use of claim 24 wherein the hyperproliferative disease is a solid tumor.

33. The use of claim 24 wherein the first agent is selected from the group consisting of aspirin and celecoxib, wherein the second agent is selected from the group consisting of metformin and phenformin, wherein the composition includes a third agent that possesses or maintains serotonin activity, and wherein the composition further comprises a carrier substance that is useful in carrying the composition to the intended site of action.

34. The use of claim 33 wherein the metformin or phenformin is linked to an antibody.

35. The use of claim 33 wherein at least one of: (i) metformin or phenformin and (ii) aspirin or celecoxib is covalently bonded to an immunoglobulin that is specific for a marker found on the hyperproliferative cells of the patient that are targeted for treatment.

36. The use of claim 35 wherein the immunoglobulin is IgG.

37. The use of any one of claims 33 to 36 wherein the medicament manufactured from the composition is administered intravenously.

38. The use of any one of claims 33 to 36 wherein the medicament manufactured from the composition is administered orally.

39. The use of any one of claims 33 to 38 wherein:

(i) the amount of the medicament manufactured from the composition needed to provide a therapeutic effect is less than the amount of the composition needed to provide a therapeutic effect when not administered with a carrier substance;

(ii) the patient experiences less toxicity to healthy cells relative to the toxicity experienced when the medicament manufactured from the composition is administered without a carrier substance; or

(iii) the patient experiences fewer adverse effects relative to the adverse effects experienced when the medicament manufactured from the composition is administered without a carrier substance.

40. The use of claim 24 wherein the composition comprises a first agent selected from the group consisting of:(i) an agent that possesses anti-inflammatory activity that is selected from the group consisting of hydrocortisone, beclomethasone, betamethasone, dexamethasone, prednisone, methylprednisolone, triamcinolone, fluocinolone, fludrocortisone, aceclofenac, acemetacin, acetylsalicylic acid, alclofenac, alminoprofen, ampiroxicam, amtolmetin guacil, apazone, atliprofen methyl ester, benoxaprofen, bermoprofen, bromfenac, bucloxic acid, butibufen, carprofen, celecoxib, choline magnesium trisalicylate, cimicoxib, cinnoxicam, clidanac, COX-2 inhibitors, darbufelone, deracoxib, dexketoprofen, diclofenac, diflunisal, eltenac, esflurbiprofen, etoricoxib, etodolac, felbinac ethyl, fenbufen, fenclofenac, fenclozic acid, fenclozine, fenoprofen, fentiazac, feprazone, filenadol, flobufen, florifenine, flosulide, flubichin methanesulfonate, flufenamic acid, fluprofen, flurbiprofen, furofenac, ibufenac, ibuproxam-beta-cyclodextrin, imrecoxib, indoprofen, isoxepac, isoxicam, ketoprofen, licofelone, lobuprofen, lumiracoxib, mabuprofen, meclofenamic acid, mefenamic acid, meloxicam, metoxibutropate, miroprofen, mofebutazone, mofezolac, nabumetone, naproxen, niflumic acid, nimesulide, nitrofenac, nitroflurbiprofen, nitronaproxen, orpanoxin, oxaprozin, oxindanac, oxpinac, oxyphenbutazone, pamicogrel, parcetasal, parecoxib, pelubiprofen, pemedolac, phenylbutazone, pirazolac, piroxicam, piroxicam beta-cyclodextrin, pirprofen, pranoprofen, rofecoxib, salicylsalicylic acid, salsalate, satigrel, sodium salicylate, sudoxicam, sulfasalazine, sulindac, suprofen, talmetacin, talniflumate, tazofelone, tebufelone, tenidap, tepoxalin, tiaprofenic acid, tilmacoxib, tilnoprofen arbamel, tinoridine, tiopinac, tioxaprofen, tolfenamic acid, tolmetin, triflusal, tropesin, ursolic acid, valdecoxib, ximoprofen, zaltoprofen, zidometacin, zomepirac, L-arginine acetylsalicylic acid, bismuth salicylate, magnesium salicylate, diethylamine salicylate, salicylic acid, imidazole salicylate, sodium aminosalicylate, isoniazid aminosalicylate, physostigmine salicylate, pregnenolone salicylate, sodium salicylate, and methylsalicylate, (ii) acetaminophen, (iii) phenacetin, and (iv) tramadol; (b) a second agent selected that is an AMPK activator; and (c) a third agent that possesses or maintains serotonin activity; and wherein the first, second and third agents of the composition are attached to their own individual carrier substances that facilitate the transport of the active agents to the intended site of action.

41. The use of claim 25 wherein the composition comprises a first agent selected from the group consisting of: (i) an agent that possesses anti-inflammatory activity that is selected from the group consisting of hydrocortisone, beclomethasone, betamethasone, dexamethasone, prednisone, methylprednisolone, triamcinolone, fluocinolone, fludrocortisone, aceclofenac, acemetacin, acetylsalicylic acid, alclofenac, alminoprofen, ampiroxicam, amtolmetin guacil, apazone, atliprofen methyl ester, benoxaprofen, bermoprofen, bromfenac, bucloxic acid, butibufen, carprofen, celecoxib, choline magnesium trisalicylate, cimicoxib, cinnoxicam, clidanac, COX-2 inhibitors, darbufelone, deracoxib, dexketoprofen, diclofenac, diflunisal, eltenac, esflurbiprofen, etoricoxib, etodolac, felbinac ethyl, fenbufen, fenclofenac, fenclozic acid, fenclozine, fenoprofen, fentiazac, feprazone,

filenadol, flobufen, florifenine, flosulide, flubichin methanesulfonate, flufenamic acid, fluprofen, flurbiprofen, furofenac, ibufenac, ibuproxam-beta-cyclodextrin, imrecoxib, indoprofen, isoxepac, isoxicam, ketoprofen, licofelone, lobuprofen, lumiracoxib, mabuprofen, meclofenamic acid, mefenamic acid, meloxicam, metoxibutropate, miroprofen, mofebutazone, mofezolac, nabumetone, naproxen, niflumic acid, nimesulide, nitrofenac, nitroflurbiprofen, nitronaproxen, orpanoxin, oxaprozin, oxindanac, oxpinac, oxyphenbutazone, pamicogrel, parcetasal, parecoxib, pelubiprofen, pemedolac, phenylbutazone, pirazolac, piroxicam, piroxicam beta-cyclodextrin, pirprofen, pranoprofen, rofecoxib, salicylsalicylic acid, salsalate, satigrel, sodium salicylate, sudoxicam, sulfasalazine, sulindac, suprofen, talmetacin, talniflumate, tazofelone, tebufelone, tenidap, tepoxalin, tiaprofenic acid, tilmacoxib, tilnoprofen arbamel, tinoridine, tiopinac, tioxaprofen, tolfenamic acid, tolmetin, triflusal, tropesin, ursolic acid, valdecoxib, ximoprofen, zaltoprofen, zidometacin, zomepirac, L-arginine acetylsalicylic acid, bismuth salicylate, magnesium salicylate, diethylamine salicylate, salicylic acid, imidazole salicylate, sodium aminosalicylate, isoniazid aminosalicylate, physostigmine salicylate, pregnenolone salicylate, sodium salicylate, and methylsalicylate, (ii) acetaminophen,(iii) phenacetin, and (iv) tramadol; a second agent that is an AMPK activator; and a third agent that possesses or maintains serotonin activity; and wherein the first and second agents are attached to their own individual carrier substances that facilitate the transport of the active agents to the intended site of action.

42. The use of claim 33 or 44 wherein the carrier substance is an antibody.

43. The use of claim 42 wherein the antibody is specific for a marker on the cells of the hyperproliferative disease.

44. Use of the composition of any of claims 1 to 24 for preparation of a medicament for inhibiting metastasis.